{
    "id": 80187,
    "name": "chronic neutrophilic leukemia",
    "source": "DOID",
    "definition": "A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene. [url:https\\://en.wikipedia.org/wiki/Chronic_neutrophilic_leukemia]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0080187",
    "evidence": [
        {
            "id": 19731,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs demonstrated sensitive to treatment with Sprycel (dasatinib) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19749,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs did not respond to treatment with Pyridone 6 (CMP6) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19750,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs did not respond to treatment with Xeljanz (tofacitinib) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19751,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs did not respond to treatment with Momelotinib (CYT387) in culture (PMID: 23656643).",
            "molecularProfile": {
                "id": 14888,
                "profileName": "CSF3R S783fs"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80187,
                "name": "chronic neutrophilic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02092324",
            "title": "Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03862157",
            "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7993,
                    "therapyName": "Azacitidine + MLN4924 + Venetoclax",
                    "synonyms": null
                }
            ]
        }
    ]
}